To inform clinicians about the types of seizures that can be induced by clozapine and to provide recommendations for treatment.
S ince the reapproval of clozapine by the US Food and Drug
Administration in 1989, several review papers have addressed the prediction and treatment of clozapine-induced seizures. Although these papers provide helpful guidelines, the recognition of clozapine-related seizures remains a difficult task. Clinicians sometimes misinterpret subtle seizure activity, such as myoclonic jerks, as nervousness or weakness. 1, 2 As illustrated in the case reported below, medical staff may be slow to recognize such seizure activity. The present paper aims to assist physicians and other clinicians in recognizing the various kinds of seizure activity that can be induced by clozapine and to provide recommendations for the treatment of these seizures. In addition to presenting our own case report, we comprehensively review relevant material published since 1978.
Methods
We performed a MEDLINE search of English-language publications from 1978 to July 2006, using the search words seizures and electroencephalography cross-referenced with clozapine. Bibliographies of these articles were used to identify additional relevant papers.
One of the goals of this review was to provide unbiased estimates of the frequencies of the types of seizure associated with clozapine. Most of the literature-cited cases described were included in the calculations of frequencies, but several were excluded for the following reasons: · The case reported by Solomons et al 3 was excluded as the authors suggested that the seizure activity of their patient was induced by a concurrently prescribed medication rather than by clozapine. 
Results

Case Report
The patient was a woman, aged 56 years, with a 24-year history of paranoid schizophrenia. Neither she nor her family had any history of seizures. Until age 54, she had received various neuroleptics, including thioridazine, chlorpromazine, risperidone, and olanzapine. At age 54, treatment with clozapine commenced, and over a 3-month period, the dosage was increased gradually to 600 mg daily. The patient smoked cigarettes; concurrent medications are listed in Table 1 . The patient subsequently experienced her first seizure (A in Table  1 ). The dosage of clozapine was reduced to 400 mg daily and anticonvulsant treatment with phenytoin was initiated. The dosage of clozapine was increased to 700 mg daily 3 weeks after the seizure. Seven days later, a tonic-clonic seizure was observed (B in Table 1 ). The phenytoin was replaced by lamotrigine; 9 months later, however, the patient began to experience myoclonic jerks (C1 in Table 1 ). The dosage of clozapine was again decreased to 400 mg daily and seizures stopped. A year later, the dosage of clozapine was inadvertently increased to 700 mg daily. Subsequently, the patient experienced 5 episodes of "drop attacks" over the following year (C2 in Table 1 ).
The first drop attack was a witnessed fall. The patient fell forward suddenly and suffered an injury to her eye, but no obvious seizure activity was present. The medical staff thought that she had tripped. The second episode consisted of 3 falls over a period of 15 minutes. The patient was reported to fall down "in slow motion" and was able to keep her head from hitting the floor. She remembered each fall and reported weakness during the falls. Some jerking of limbs and jerky facial movements were observed. After the second series of falls, an electroencephalogram (EEG) was recorded. The EEG showed a generalized dysrhythmia with occasional, brief, slow wave discharges diffusely and some superimposed sharp components, but there were no associated clinical features. The third episode was a witnessed fall. Medical staff suspected that this and previous falls were, at least partly, intentional. During the fourth episode, it was reported that the patient lost balance and her knees appeared to buckle. Further twitching was noted, and the medical staff suspected that the fall was due to syncope. In the final drop attack, the patient was reported to lower herself to the floor, where further twitching was observed. A month later, these episodes were determined to be atonic and myoclonic seizures, resulting from an excessively high dosage of clozapine. After the dosage was decreased to 500 mg daily, the patient experienced no further attacks. Table 1 ).
The first 2 seizures occurred at what would be considered to be usual or therapeutic dosages and plasma levels of clozapine (A and B in
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The relative frequencies of the different types of seizures induced by clozapine and the mean dosage of clozapine associated with each type of seizure are shown in Table 2 ; the mean dosage was calculated by totalling each individual patient's dosage and dividing this by the total number of patients experiencing each type of seizure.
It is clear that the tonic-clonic variety is the most frequently reported type of clozapine-induced seizure. Myoclonic and atonic seizures constitute about one-quarter of the reported cases, but these types of seizures may be underreported. 6 The development of myoclonic jerks is often a forerunner of tonic-clonic seizures. 7, 8 Atonic seizures represent another important potential precursor of a tonic-clonic seizure. 9 Drop attacks can result from atonic seizures but may be difficult to recognize; they may be interpreted as myoclonic flexion of the knees instead of a loss of muscle tone 10 or, as in our case, they may be thought to be psychogenic. In addition to myoclonic jerks and atonic seizures, stuttering can also be induced by clozapine and may be a precursor of tonic-clonic seizures. [11] [12] [13] 
Concurrent Medication and Clozapine
Various drugs affect the plasma level of clozapine and may also independently affect the seizure threshold. Medications reported to be related to clozapine-induced seizures are listed in Table 3 .
Drugs that reduce the plasma level of clozapine may induce seizure activity if they are discontinued. In the cases described by Skogh et al 14 and McCarthy, 15 patients experienced seizures directly after they ceased smoking. Smoking induces the enzyme responsible for clozapine metabolism, cytochrome P450 1A2 16 ; the cessation of smoking may thus result in elevation of the plasma level of clozapine and the induction of seizures.
Dosage and Plasma Level of Clozapine
The risk of seizures increases with higher dosages of clozapine: there is a 1% risk at dosages of less than 300 mg daily, 2.7% at 300 to 600 mg daily, and 4.4% at dosages of more than 600 mg daily. 5 Seizures can, however, occur at dosages as low as 37.5 mg daily. 17 Several authors have proposed routine monitoring of the plasma clozapine level, 18, 19 which is affected by various patient-related variables other than the dosage. 20 The plasma level of clozapine can assist in the prediction of clinical toxicity during clozapine treatment. Although the therapeutic range of clozapine has been reported by some investigators to be 1070 to 1285 nmol/L, 18, 19, 21 the lower limit of efficacy is still in doubt; in fact, Owen et al 22 did not find any evidence of a therapeutic range. From our review, a plasma level of clozapine as low as 144 nmol/L 23 has been associated with seizure activity. Moreover, as reported by Greenwood-Smith et al, 24 the upper limit of the therapeutic range has not been established either. As shown in Table 2 , the mean dosages of clozapine associated with seizures are not high. Thus the plasma level of clozapine can be used as a guide but not as a definite predictor of therapeutic efficacy or seizures.
Electroencephalography
There is controversy as to whether the EEG is a good predictor of seizure activity. Some authors 25, 26 have suggested that EEG changes induced by clozapine should not be used as a harbinger of seizures. In the cases presented by Silvestri et al, 27 interictal epileptiform discharges showed only a limited 
Treatment of Clozapine-Induced Seizures
Once a first seizure has occurred, the dosage of clozapine should be decreased and any other seizure-provoking factors (such as sleep deprivation) eliminated. 29 The dosage is usually reduced by about 40% to 50% 14, [30] [31] [32] to maintain the therapeutic effect of clozapine.
If a second seizure occurs, then treatment with an anticonvulsant agent should be considered. As already discussed, the types of seizures that can be precipitated by the administration of clozapine are varied, including tonic-clonic, myoclonic, and atonic seizures; moreover, myoclonic seizures may presage tonic-clonic seizures. Because of the eclectic pathogenesis of these diverse seizures, a broad-spectrum anticonvulsant agent is preferable. Valproic acid and lamotrigine are thus first-line drugs for the treatment of clozapine-induced seizures. Traditional agents, such as phenytoin, have greater efficacy against tonic-clonic seizures, compared with myoclonic seizures, and are probably less effective overall.
When coadministering anticonvulsants, the possibility of drug-drug interactions exists. Valproate, for example, generally reduces the plasma level of clozapine, 23, 33 and this pharmacokinetic effect may, therefore, interfere with the therapeutic efficacy of clozapine. Conversely, as reported by Conca et al, 23 when discontinuing valproate, the plasma level of clozapine may increase and the seizure threshold of the patient may concurrently be lowered. Phenytoin is another anticonvulsant drug that is reported to be associated with a reduced plasma level of clozapine. 34 Gabapentin has been recommended by Landry in preference to valproate on the grounds that it does not affect the pharmacokinetics of clozapine. 17 Lamotrigine has been recommended by Langosch and Trimble, also because of its lack of drug interactions. 35 In a trial conducted by Dursun and Deakin, 36 lamotrigine was found to work synergistically with clozapine. Carbamazepine is not recommended for use with clozapine as it, too, may cause bone marrow suppression. 29 Some authors, however, have suggested that carbamazepine is safe with clozapine if the white blood cell count is regularly measured. 1, 30 When recommencing clozapine treatment after a seizure, a slower than usual titration of clozapine is suggested. 32, 37 
Discussion
As shown in our case report, it is difficult to recognize some of the seizures induced by clozapine. Not only were the presenting symptoms subtle, but investigations were of limited value in making the diagnosis: the final plasma clozapine level of our patient was 1438 nmol/L, only slightly above the top of the putative therapeutic range of 1285 nmol/L, 18, 19, 21 and the EEG results showed slow wave discharges that were interpreted as being secondary to the therapeutic effect of clozapine.
From our review, it can be seen that seizure activity other than tonic-clonic (such as myoclonic and atonic seizures) constitutes a substantial proportion of all reported clozapine-induced seizures. The dosages of clozapine associated with these seizures appear to differ little from those associated with tonic-clonic seizures. Plasma clozapine levels and EEG findings may be of limited practical value in predicting or diagnosing seizures. Therefore, careful observation and a high index of suspicion are crucial for the recognition of seizure activity.
Note that the findings presented in this paper may be subject to reporting bias: some types of seizures, such as tonic-clonic, may be overreported, whereas other varieties, such as atonic seizures, may be underreported. This is, however, a comprehensive review of the published literature and represents our best attempt at compiling the existing data.
Conclusion and 10 Recommendations
We make the following recommendations to assist clinicians in the prevention, recognition, and treatment of clozapine-induced seizures: 7. If a second seizure occurs, commencement of an anticonvulsant drug should be considered. Valproate is the anticonvulsant most commonly used for clozapine-induced seizures; lamotrigine and gabapentin have also proven to be effective and are less likely to affect the plasma level of clozapine. In general, carbamazepine should be avoided.
8. When concurrent medication is administered, care should be taken with drugs that increase the plasma level of clozapine. Adding these medications may result in seizures. 9 . When drugs that can decrease the plasma level of clozapine are discontinued, the dosage of the drug in question should be reduced slowly and the plasma level of clozapine should be carefully monitored. This caution applies also to smoking cessation, which is more likely to be abrupt. When drugs that can decrease seizure threshold (for example an anticonvulsant) are discontinued, the dosage of the drug in question should be reduced slowly and the patient watched carefully for any sign of seizure activity. 10 . Once a therapeutic effect is observed, the dosage of clozapine should not be increased further until clinical improvement has reached a plateau, and then a decision should be made about whether a further increase is worthwhile.
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